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Editorial: NMS, and Why We Should Call It 
(Malignant) Catatonia 
 
Robert Arnold Johnson, M.D. (PGY4) 
 
 
   The review in the current issue by Guzofski and Peralta, “Neuroleptic Malignant 
Syndrome, with Attention to Its Occurrence with Atypical Antipsychotic 
Medication: A Review,” reminds me of the influence of a name. I am thinking here 
of the name, “neuroleptic malignant syndrome” (NMS), which was coined by 
Delay in 1960, following reports of “catatonic-like” states resulting from 
phenothiazines, and popularized through an influential review by Caroff in 1980 
(1, 2).  
   A very similar syndrome, recognized as an advanced (excited, lethal, malignant, 
pernicious) form of catatonia had been described well before the advent of the 
typical antipsychotic medications. And catatonic features often are an overt feature 
of NMS (3-5). In addition, simple catatonia is recognized as a risk factor for NMS 
if typical neuroleptic is given (5). Even so, the name of NMS took on a life of its 
own, a meme, we might say, that began to spread from one psychiatrist’s mind to 
another independently of the meme(s) for catatonia, despite the efforts of some to 
stem the tide (3). I offer as proof of this last sentence two first-hand observations. 
First, I find that few of my peers are aware of a link between, or similarity of, 
NMS and malignant catatonia (MC). Second, Doctors Guzofski and Peralta did not 
include much mention of MC in their original submission. And, I suspect, nothing 
unusual at all resides in either of these observations. A very large number of 
psychiatrists and psychiatry residents do not realize NMS and MC are linked 
concepts, that’s my guess. I have been luckier myself. Two of my mentors when I 
was a PGY2 on the Consultation-Liaison rotation here at Jefferson, Dr. David 
Lynn and Dr. Dimitri Markov, taught me about MC and encouraged me to dig into 
its literature; as I did that, I learned about its link with NMC. And for that I have 
most to thank Dr. Max Fink and his colleague, Dr. Michael Alan Taylor (6, 7). 
They are not the only, or even the first, authors to speak of a link between MC and 
NMS (3), but Dr. Fink, especially, has been the most declamatory on the topic, the 
one most emphatic that the matter of language, the matter of the name, has a lot to 
do with how we clinicians behave.  
   His point of view is that NMS is a variant of, or a subtype of, MC: MC that 
happens to have been triggered by an antipsychotic medication. (The same is true, 
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he believes, of serotonin syndrome: a subtype of MC, one that has been triggered 
by serotonergic excess.) And this view has a highly practical implication, namely, 
that treatment that is effective for catatonia should not be withheld from those 
suffering from NMS. He is thinking of benzodiazepine (lorazepam is used most 
often) and, should that medication prove ineffective within a few days, 
electroconvulsive therapy (ECT). The dose of lorazepam that is required is often 
quite high, so the schedule by which it is advanced will need to be aggressive 
(taking care not to produce oversedation or respiratory compromise, of course); it 
can be given parenterally, and should be in some instances (8). 
   So, having brought the memes of MC and NMS together in your mind, you 
become vigorous in the application of benzodiazepine. But it is in the early use 
(“early” in a relative sense) of ECT that your thinking is most changed by 
comparison with your thinking had the two memes remained estranged. And that’s 
because the NMS meme, as an isolated thing, does not lead to thinking of ECT (or 
benzodiazepine) early on. It is modeled on another meme (by “meme”—maybe I 
should be speaking of a whole family of them—I mean, of course, a word or 
phrase or idea that appears to spread from mind to mind in the Dawkins sense, as a 
selfish gene might, were it possible for a gene to spread from mind to mind), that 
of malignant hyperthermia (MH), which brings forward first the idea of supportive 
care, especially with regard to control of body temperature and fluid volume, and 
this, of course, is a fine outcome even were MC and NMS two separate things. 
And next among the weapons summoned up by the NMS meme(s) is the drug 
dantrolene (a direct-acting muscle-relaxant that affects calcium flux from the 
endoplasmic reticulum), also bromocriptine (a dopamine agonist to fix the 
hypodopominergic state that the neuroleptic caused), amantadine (another 
dopaminergic drug), or both. And uncontrolled but careful clinical studies provide 
good support for the use of dantrolene and dopaminergic drugs in NMS (1, 5). It’s 
not that their use is to be avoided, it’s that ECT should not be put off long if they, 
as adjuncts to benzodiazepine, have not relieved the disorder within a few days. 
And Dr. Fink’s point is this: ECT is likely to be put off too long if the concepts of 
NMS and MC are not linked in the clinician’s mind, brought together in the one 
idea that the former is a special subtype of the latter. Two excellent books on 
catatonia, both published recently, support this opinion and document its history 
(9, 10). 
   No randomized studies of ECT in MC or NMS exist, but clinical experience with 
its good effectiveness in these conditions, which I, following Fink and several 
others, shall link together as one, is fairly extensive (1, 2, 5, 6, 11-14). It appears to 
be safe generally, but at least two patients have died as a consequence, so some 
caveats are in order. First is that neuroleptic must be stopped as far in advance of 
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the procedure as possible (which should have been the case at the time of diagnosis 
anyway), as the two deaths mentioned were both in patients in whom neuroleptic 
had been continued (15). The neuroleptic in these cases was a typical one, but the 
caveat almost surely should extend to the newer, atypical antipsychotics also. 
Second is that succinylcholine should be avoided as the paralyzing agent for ECT 
if at all possible; this agent is known to predispose to abrupt hyperkalemia 
(possibly the mechanism of death for the two cases mentioned), and conditions 
favoring hyperkalemia are already extant in the situation (muscular injury from 
rigidity and high body temperature; possible renal compromise from myoglobin-
uria and extracellular volume depletion; possibly a direct potassium-releasing 
effect of ECT on skeletal muscle). The third follows from what has just been said: 
serum potassium should be monitored very closely and great care should be taken 
to ensure that extracellular volume has been repleted by adequate intravenous 
supple-mentation (16). 
   Thinking of MC, NMS, and serotonin syndrome (SS) as variations on the same 
theme, that of catatonia, makes it easier for me to remember how they present, 
mainly as the same picture with some interesting differences: the excited, 
prodromal phase may be missing and muscular rigidity earlier in NMS; 
gastrointestinal distress, and maybe myoclonic seizures, more prominent in SS. 
Seeing the one family makes it easier to pick up the distinctions among its 
members. And, speaking of families, what a large number of conditions has been 
reported to cause catatonia! Most of the reports are of the “benign” (simple, 
retarded) form (BC), but I see no reason to presume that a condition capable of 
causing BC could not also cause MC, as the latter may occur as an “advanced” 
stage, or complication, of the former. I have gathered the conditions that I have 
come across in the literature into two tables. The citations for these, in many 
instances, are in the articles or books cited in the References section.  
 
 
Table 1. Psychiatric Predispositions to Catatonia  
?  mood disorders          
 mania or depression: ~ 50% of catatonias; 25-50% of all catatonics are manic  
? schizophrenia & other psychoses         
 ~ 15% of catatonic adults; higher % in children 
?  autism spectrum disorders  
?         obsessive-compulsive disorder (at least the PANDAS form) 
?         dissociative disorders/hypnosis 
? narcolepsy        
? periodic catatonia (a rare familial form, maybe autosomal dominant) 
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Table 2. Medical Predispositions to Catatonia 
 (Approximately 25% of catatonias have no psychiatric cause)      
  
Neurological          
• Von Economo’s encephalitis 
• HIV 
• Chagas disease (acute) 
• Lyme disease 
• Herpes simplex 
• GPI (CNS syphilis) 
• subacute sclerosing panencephalitis  
• acute disseminated encephalomyelitis 
• seizure disorder (esp in children), incl 
postictal 
• postmalarial syndrome, w/ psychosis 
• head injury, including subdural hematoma    
• subarachnoid hemorrhage 
• basilar artery thrombosis 
• stroke (often cardioembolic) 
• Sheehan’s syndrome 
• paraneoplastic encephalopathy 
• periventricular diffuse pinealoma 
• tumor of septum pellucidum 
• subthalamic tumor, w/ hydrocephalus 
• alcoholic/Wernicke encephalopathy   
• multiple sclerosis    
• Parkinson’s disease  
• progressive supranuclear palsy 
• dementia with Lewy bodies 
• familial cerebellar-pontine atrophy 
• hereditary spinocerebellar degeneration   
• tuberous sclerosis    
• Creutzfeldt-Jacob disease    
• bilateral globus pallidus lesions 
• frontal, parietal, or thalamic lesions    
• arachnoid cyst 
 
Systemic 
• SLE     
• FUO  
• TTP     
• Wilson’s disease 
• liver transplantation 
• hepatic encephalopathy 
• uremia 
• diabetic ketoacidosis 
• membranous GN 
• hyponatremia 
• burns 
• staphylococcal infection 
• tetanus 
• tuberculosis  
• infectious mononucleosis 
• typhoid fever 
• PANDAS 
• vitamin B12 deficiency 
• hyperparathyroidism/hypoparathyroidism 
• pheochromocytoma   
• thyrotoxicosis 
• acute intermittent porphyria 
• Addison’s disease/Cushing’s disease  
   
• MEN, 1  
• hereditary coproporphyria  
• carcinoid tumor    
• homocystinuria   
• pellagra                      
• Tay-Sach disease (adult form)  
  
     
Toxic Effect of a Medication or Substance 
• azithromycin   
• ciprofloxacin     
• bupropion  
• venlafaxine   
• clomipramine 
• methylphenidate 
• lithium 
• levetiracetam  
• neuroleptic (NMS) 
• serotonergic (SS)  
• corticosteroid, ACTH 
• fluorides  
• baclofen 
• disulfiram    
• cyclosporine 
• reserpine 
• metoclopramide 
• psilocybin 
• PCP 
• MDMA (ecstasy) 
• opiates 
• mescaline 
• illuminating gas 
• alcohol 
• aspirin (overdose) 
• strychnine     
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Withdrawal from a Medication 
• lorazepam, other benzodiazepine   
• mixed sedative 
• carbamazapine 
 
 
  
• dopaminergic drugs 
• anticholinergic drugs 
• gabapentin 
 
 
 
   Hard to shake off vertigo from simply looking at these tables. Harder still to 
imagine the disorder in the clinician’s mind, were there no unifying idea like 
“catatonia” to bring them together under the one roof: otherwise we would be 
trying to memorize, I suppose, the neuropsychiatric features one by one that each 
was reputed to have caused. And we would have no idea at all how to proceed with 
therapy. As it is, we can know this: the catatonic illness that each and every one of 
these disorders can, on occasion, produce is treated in exactly the same way, 
varying only according to its response to initial therapy, namely, to lorazepam!  Of 
course, with the exception of withholding typical neuroleptic in all catatonias until 
the state is relieved, and withholding any antipsychotic, typical or atypical, in the 
MC variant, it doesn’t hurt to treat the specific predisposition to the catatonic state, 
too, whenever that is possible. Such is the value of a name, the right name. Which 
doesn’t mean the future could not bring a better one, or reveal that we’d be better 
off with more than one, and which names those should be. 
   Just why the two names, NMS and MC, fell apart and propagated separately is 
unclear, to me anyway. It seems that some of the important writers about them in 
decades past, Caroff and colleagues, and Fricchione and colleagues, took distinct 
care to see that separate propagation did not occur. And yet it did. (Which is why 
Dr. Fink has had to come to the rescue.) Perhaps psychiatry contains such variety it 
has trouble keeping its language from splitting into dialects that soon fracture its 
citizenry. Perhaps our textbook editors have under-appreciated the phenomenon of 
catatonia (the topic surely gets short shrift in some), owing to having succumbed to 
addictive properties in the format of the DSM-IV. The latter has an unstable 
placement for catatonia (6), apparently out of loyalty, conscious or not, to the 
outmoded conception that catatonia is mainly a schizophrenic condition. Perhaps 
NMS, flirtatious as it is with the MH meme(s), has biological cachet for those who 
are made anxious by the very subject of psychiatry, which is the mind.  
 
 
SOURCE INFORMATION 
From the Department of Psychiatry and Human Behavior, Thomas Jefferson University Hospital, Philadelphia. 
Address inquiries to: rajsep0802@yahoo.com. 
 
 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  67 
REFERENCES 
1. Susman VL. Clinical management of neuroleptic malignant syndrome. 
Psychiatric Q 2001; 72:325-36 
 
2. Lazarus A. Treatment of neuroleptic malignant syndrome with electroconvulsive 
therapy. J Nerv Mental Dis 1986; 174:47-9 
 
3. Fricchione GL. Neuroleptic catatonia and its relationship to psychogenic 
catatonia. Biol Psychiatry 1985; 20:304-13 
 
4. Blumer D. Catatonia and the neuroleptics: psychobiologic significance of 
remote and recent findings. Comprehen Psychiatry 1997; 38:193-201 
 
5. Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic 
syndrome. Biol Psychiatry 1998; 44:378-81 
 
6. Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. 
Am J Psychiatry 2003; 160:1233-41 
 
7. Fink M, Taylor MA. Neuroleptic malignant syndrome is malignant catatonia, 
warranting treatments efficacious for catatonia (letter to the editor). Prog 
Neuropsychopharm Biol Psychiatry 2006; 30:1182-3 
 
8. Fricchione GL, Cassem NH, Hooberman NH, Hobson D. Intravenous lorazepam 
in neuroleptic-induced catatonia. J Clin Psychopharm 1983; 3:338-42 
 
9. Fink M, Taylor MA (2003). Catatonia: A Clinician’s Guide to Diagnosis and 
Treatment. Cambridge, UK: Cambridge University Press. 
 
10. Caroff SN, Mann SC, Francis A, Fricchione GL (2004). Catatonia: From 
Psychopathology to Neurobiology. Washington, DC: APPI 
 
11. Mann SC, Caroff SN, Bleier HR, Antelo RE, Un H. Electroconvulsive therapy 
of the lethal catatonia syndrome: case report and review. Convulsive Therapy 
1990; 6:239-47 
 
12. Rummans TA. Medical indications for electroconvulsive therapy. Psychiatric 
Ann 1993; 23:27-32 
 
Jefferson Journal of Psychiatry, Volume 20, Number 1 ISSN 1935-0783 
© 2006 by the authors 
On the Web:  jdc.jefferson.edu/jeffjpsychiatry  68 
 
13. Ozer F, Meral H, Aydin B, Hanoglu L, Aydemir T, Oral T. Electroconvulsive 
therapy in drug-induced psychiatric states and neuroleptic malignant syndrome. J 
ECT 2005; 21:125-7 
 
14. Nosijima K, Ishiguro T. Electroconvulsive therapy for the treatment of 
neuroleptic malignant syndrome with psychotic symptoms: a report of five cases. J 
ECT 1999; 15:158-63 
 
15. Davis JM, Janicak PG, Sakkas P, Gilmore C. Electroconvulsive therapy in the 
treatment of the neuroleptic malignant syndrome. Convulsive Therapy 1991; 
7:111-20 
 
16. Hudcova J, Schumann R. Electroconvulsive therapy complicated by life-
threatening hyperkalemia in a catatonic patient. Gen Hosp Psychiatry 2006; 
28:440-6 
 
 
   
 
